Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a cluster of new chemical materials [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which produces a variety of products including gelatin and collagen [1] Group 2: Chemical Industry Segment - The large chemical segment generated revenue of 17.369 billion yuan in 2024, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] - The company has established long-term stable partnerships with major clients such as Hisense, Gree, TCL, Huawei, BOE, and CATL [3] - Current production capacities include 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [4] Group 3: Product Development and Market Strategy - The company is enhancing its market share in the new energy vehicle sector by improving the performance of modified materials such as PP, PC, ABS, and PA [2] - In the energy storage battery sector, the company is advancing the application of flame-retardant and anti-explosion materials [2] - Future plans include expanding production capacities for polystyrene and developing new products like high-performance polyolefin elastomers and biodegradable materials [5] Group 4: Financial Performance - In 2024, the health segment generated revenue of 885 million yuan, accounting for 4.6% of total revenue [5] - Overall, the company achieved a total revenue of 19.22 billion yuan in 2024, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% [5] - The first quarter of 2025 reported total revenue of 4.412 billion yuan, a slight decrease of 0.23% year-on-year, with a net profit of 111 million yuan, down 9.79% [6]

【DT新材料】 获悉，5月25日， 国恩股份 发布公告称， 公司于2025年5月26日召开董事会和监事 会，审议通过发行H股股票并在香港联交所主板挂牌上市的议案 。公司计划通过发行境外上市外资 股（H股）股票，打造国际化资本运作平台，加快构建国内国际双循环格局。 国恩股份 成立于2000年，总部位于青岛市城阳区青大工业园，是一家以 大化工 和 大健康 为两大核 心产业的上市公司。公司以国恩系纵向一体化产业平台为中枢，实施"一体两翼"发展战略，形成了绿 色石化、有机高分子改性、有机高分子复合材料、可降解材料、光显材料、运动健康材料以及新能源 汽车轻量化结构部品等化工新材料产业集群。 同时，控股胶原领域上市公司 东宝生物 ，通过明胶、 代血浆明胶、胶原蛋白、空心胶囊、双蛋白膳食纤维、美妆产品等在"医、美、健、食"的广泛应用， 深入布局大健康产业细分领域。 公 司 大化工板块 涵盖有机高分子改性材料、有机高分子复合材料、绿色石化材料及新材料等多个领 域， 通过技术创新和产品升级，形成了从通用改性材料到高端特种材料的矩阵化产品体系，广泛应 用于家电、汽车、新能源等领域。 在动力电池、储能电池等相关产业方向，加快推进 ...